Barinthus Biotherapeutics Plc Stock Today
| BRNS Stock | 1.03 0.04 4.04% |
PerformanceWeak
| Odds Of DistressVery High
|
Barinthus Biotherapeutics is selling for under 1.03 as of the 26th of March 2025; that is 4.04 percent increase since the beginning of the trading day. The stock's lowest day price was 0.99. Barinthus Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 26th of December 2024 and ending today, the 26th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of April 2021 | Category Healthcare | Classification Health Care |
Barinthus Biotherapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 40.34 M outstanding shares of which 14.05 K shares are currently shorted by private and institutional investors with about 0.67 trading days to cover. More on Barinthus Biotherapeutics plc
Moving against Barinthus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Barinthus Stock Highlights
| CEO Director | William MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBarinthus Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Barinthus Biotherapeutics' financial leverage. It provides some insight into what part of Barinthus Biotherapeutics' total assets is financed by creditors.
| |||||
Barinthus Biotherapeutics plc (BRNS) is traded on NASDAQ Exchange in USA. It is located in Zeus Building, Didcot, United Kingdom, OX11 0DF and employs 14 people. Barinthus Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.35 M. Barinthus Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 40.34 M outstanding shares of which 14.05 K shares are currently shorted by private and institutional investors with about 0.67 trading days to cover.
Barinthus Biotherapeutics generates negative cash flow from operations
Check Barinthus Biotherapeutics Probability Of Bankruptcy
Ownership AllocationBarinthus Biotherapeutics holds a total of 40.34 Million outstanding shares. 30% of Barinthus Biotherapeutics plc outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Barinthus Ownership Details
Barinthus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 8 K | |
| New England Capital Financial Advisors Llc | 2024-12-31 | 104 | |
| Rhumbline Advisers | 2024-12-31 | 60.0 | |
| Blackrock Inc | 2024-12-31 | 0.0 | |
| Royal Bank Of Canada | 2024-09-30 | 0.0 | |
| Bluecrest Capital Management Ltd. | 2024-12-31 | 0.0 | |
| Citadel Advisors Llc | 2024-12-31 | 0.0 | |
| Ubs Group Ag | 2024-12-31 | 0.0 | |
| M&g Plc | 2024-12-31 | 5.2 M | |
| Alphabet Inc | 2024-12-31 | 1.5 M | |
| Sc China Holding Ltd | 2024-12-31 | 1.4 M |
Barinthus Biotherapeutics Historical Income Statement
Barinthus Stock Against Markets
Barinthus Biotherapeutics Corporate Management
| Gemma Brown | Chief Officer | Profile | |
| Bernie McDonald | Head IP | Profile | |
| Geoffrey Lynn | Senior Immunotherapies | Profile | |
| Chris Ellis | Chief Officer | Profile | |
| Graham Griffiths | Chief Officer | Profile | |
| Elizabeth MBA | Head Operations | Profile |
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.